A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 80
- Population
- ALL · 50 Years
- Duration
- 2022-05-09 to 2028-03-01
- Intervention
- Aflibercept; Brolucizumab; early treat and extend (T&E)
- Comparator
- Aflibercept ® rapid treatment extension (T&E); Brolucizumab ® rapid treatment extension (T&E)
- Outcomes measured
- Number of injections given until week 52 — 52 weeks; Injections until week 104 — 104 weeks; Number of treatment failures — 52 weeks; Number of treatment failures — 104 weeks; Time until drying of retina — 52 weeks; Time until drying of retina — 104 weeks; portion of eyes without disease activity — 52 weeks; portion of eyes without disease activity — 104 weeks; eyes under treatment intervals of ≥12 weeks — 52 weeks; eyes under treatment intervals of ≥12 weeks — 104 weeks; Change in visual acuity — 52 weeks; Change in visual acuity — 104 weeks; Change in central subfield thickness (CST) — 52 weeks; Change in central subfield thickness (CST) — 104 weeks; Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters — 52 weeks; Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters — 104 weeks; Maximal treatment interval extension — 52 weeks; Maximal treatment interval extension — 104 weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.